Life Technologies announced that it will be launching a new Clinical Genomics company named “Claritas Genomics” in partnership with Boston Children’s Hospital. Claritas Genomics will develop diagnostic testings using next-generation genetics/genomics and the majority of Claritas Genomics will be owned by Boston Children’s hospital. The hospital’s CLIA certified genetic diagnostic lab and its personnel will play a lead role in the company. Life Technologies plan to to use Claritas Genomics to validate the Ion Proton Sequencer’s clinical utility.
Announcing the new clinical Genomics company at the 2013 J.P. Morgan Healthcare Conference in San Francisco, Greg Lucier, chairman and chief executive officer of Life Technologies siad
Our investment in Claritas Genomics is a prime example of strategic partnerships Life Technologies is entering into to accelerate the use of accurate genomic information in medical practice. This new venture serves as a model for future endeavors to demonstrate the validation of our Ion Torrent technology in an integrated laboratory workflow designed for clinical applications related to pediatrics and inherited diseases.
Sandra Fenwick, president and chief operating officer of Boston Children’s, said
While a number of academic and private ventures are offering genomic sequencing and molecular diagnostics to the public, no other partnership has integrated all the elements—fast, accurate genomic sequencing, bioinformatics, CLIA expertise and access to researchers and clinicians who can interpret the data in a meaningful way. We want to advance the standard of care, create a seamless experience and extend it to children and adults across the U.S. and around the world.